Medtronic is sponsoring the SMART randomized head-to-head trial comparing its Evolut PRO and Evolut PRO+ self-expanding transcatheter aortic valve replacement systems against Edwards Lifesciences’ Sapien 3 and Sapien 3 Ultra balloon-expandable TAVR systems in patients with severe symptomatic aortic stenosis.
Medtronic Announces Two New Trials To Expand TAVR Indications
The SMART trial will compare Medtronic’s Evolut TAVR systems to Edward’s Sapien 3 devices. Evolut EXPAND TAVR I will evaluate Evolut in patients with symptomatic moderate aortic stenosis or asymptomatic severe disease.
